Jianwei Che

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9554040/publications.pdf

Version: 2024-02-01

16	733	840776 11	888059 17
papers	citations	h-index	g-index

17	17	17	870
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Selective Macrocyclic Inhibitors of DYRK1A/B. ACS Medicinal Chemistry Letters, 2022, 13, 577-585.	2.8	3
2	Cereblon covalent modulation through structure-based design of histidine targeting chemical probes. RSC Chemical Biology, 2022, 3, 1105-1110.	4.1	23
3	Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor. ACS Medicinal Chemistry Letters, 2021, 12, 30-38.	2.8	9
4	Fragment-based covalent ligand discovery. RSC Chemical Biology, 2021, 2, 354-367.	4.1	65
5	Discovery and resistance mechanism of a selective CDK12 degrader. Nature Chemical Biology, 2021, 17, 675-683.	8.0	69
6	Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2. Angewandte Chemie - International Edition, 2021, 60, 15905-15911.	13.8	25
7	The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood, 2021, 138, 1966-1979.	1.4	16
8	Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2. Angewandte Chemie, 2021, 133, 16041-16047.	2.0	5
9	Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell, 2020, 183, 1714-1731.e10.	28.9	163
10	Selective Degradation of GSPT1 by Cereblon Modulators Identified via a Focused Combinatorial Library. ACS Chemical Biology, 2020, 15, 2722-2730.	3.4	46
11	Discovery of Covalent MKK4/7 Dual Inhibitor. Cell Chemical Biology, 2020, 27, 1553-1560.e8.	5.2	10
12	TargetingMETDysregulation in Cancer. Cancer Discovery, 2020, 10, 922-934.	9.4	94
13	Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13. Journal of Medicinal Chemistry, 2020, 63, 6708-6726.	6.4	23
14	Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14â€“Mutant NSCLC. Clinical Cancer Research, 2020, 26, 2615-2625.	7.0	129
15	Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine. Journal of Medicinal Chemistry, 2020, 63, 1624-1641.	6.4	27
16	Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface. ACS Medicinal Chemistry Letters, 2020, 11, 1269-1273.	2.8	22